leadf
logo-loader
viewOptiBiotix Health PLC

OptiBiotix Health 'proves commercial model' in 2020, focus now on 'next generation products in 2021'

OptiBiotix Health PLC's (LON:OPTI) Stephen O'Hara explains how the company managed to prove their commercial model with a solid foundation to begin 2021 in a strong position.

He sets out the agenda for 2021 which is to 'focus on the next generation of products'.

The company's key products, in which there are now 78 deals ongoing are weight management lines SlimBiome and SlimBiome Medical, LPLDL (cholesterol) and SweetBiotix (sweetener).

 

Quick facts: OptiBiotix Health PLC

Price: 57.8 GBX

AIM:OPTI
Market: AIM
Market Cap: £49.42 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of OptiBiotix Health PLC named herein, including the promotion by the Company of OptiBiotix Health PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

OptiBiotix Health signs 78 partnership agreements to date and targets...

OptiBiotix Health PLC (LON:OPTI) Neil Davidson talks to Proactive London about their 'busy year' which includes global manufacturing deals in Singapore and Australia. Davidson says they've gone from just being a 'a good idea' in regards to tackling some of the major issues in regards to...

on 17/11/20

2 min read